ArticleJournal of nutrition and metabolism2012
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.
Article in Journal of nutrition and metabolism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 61 citations in OpenAlex.
- Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.Journal of clinical medicine · 2025Article
- Two for the price of one: GLP-1 analogues, a new approach in treating severe COPD patients with diabetes.ERJ open research · 2025Article
- Dipeptidyl peptidase-4 inhibitor linagliptin improves fibrosis, apoptosis, and cardiac function in a large animal model of chronic myocardial ischemia.The Journal of pharmacology and experimental therapeutics · 2025Article
- Exploring the Real-World Effectiveness of Empagliflozin and Linagliptin Fixed-Dose Combination in Type 2 Diabetes Patients of Bangladesh: A Prospective Multi-Center Observational Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Surfaceome analysis of extracellular vesicles from senescent cells uncovers uptake repressor DPP4.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Links between Insulin Resistance and Periodontal Bacteria: Insights on Molecular Players and Therapeutic Potential of Polyphenols.Biomolecules · 2022Review
- Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion.Journal of family medicine and primary care · 2021Review
- Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.Nutrients · 2021Review
- Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes.Journal of clinical medicine · 2019Review
- DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and AmelioratesJournal of diabetes research · 2018Article
- Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.Nature reviews. Drug discovery · 2016Review
- G protein-coupled receptors as targets for anti-diabetic therapeutics.Nature reviews. Drug discovery · 2016Review
- Overcoming Insulin Insufficiency by Forced Follistatin Expression in β-cells of db/db Mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Article
- Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.British journal of pharmacology · 2014Review
- A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy.Diabetology & metabolic syndrome · 2014 · on this mapReview
- Effects of glucagon-like peptide-1 receptor agonists on renal function.World journal of diabetes · 2013Review
- Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Drug design, development and therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years the incretin therapies have provided a new treatment option for patients with type 2 diabetes mellitus (T2DM). The incretin therapies focus on the increasing levels of the two incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in increased glucose dependent insulin synthesis and release. GLP-1 receptor agonists such as liraglutide and exenatide exert an intrinsic biological effect on GLP-1 receptors directly stimulating the release of insulin from pancreatic beta cells. DPP-4 inhibitors such as sitagliptin and linagliptin prevent the inactivation of endogenous GLP-1 and GIP through competitive inhibition of the DPP-4 enzyme. Both incretin therapies have good safety and tolerability profiles and interact minimally with a number of medications commonly prescribed in T2DM. This paper focuses on the pharmacological basis by which the incretin therapies function and how this knowledge can inform and benefit clinical decisions. Each individual incretin agent has benefits and pitfalls relating to aspects such as glycaemic and nonglycaemic efficacy, safety and tolerability, ease of administration, and cost. Overall, a personalized medicine approach has been found to be favourable, tailoring the incretin agent to benefit and suit patient's needs such as renal impairment (RI) or hepatic impairment (HI).
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.